A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN01-24

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• P. Bedano, M. Neubauer, R. Ansari, R. Govindan, L. Einhorn, D. Bruetman, A. White, T. Breen, B. Juliar, N. Hanna. Phase III Study of Cisplatin (P) plus Etoposide (E) with Concurrent Chest Radiation (XRT) followed by Docetaxel (D) vs. Observation in Patients (pts) with Stage III Non-small Cell Lung Cancer (NSCLC): An Interim Toxicity Analysis of Consolidation Therapy LUN01-24. Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2006 Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006, Atlanta, Georgia
• F.O. Ademuyiwa, N. Hanna, C. Johnson, T. Breen, C. Yiannoutsos, A. White. Multivariate Analysis of Prognostic Variables Associated with Survival from a Phase III Study of Cisplatin (P) plus Etoposide (E) plus Chest Radiation (XRT) with or without Consolidation dDocetaxel (D) in Patients with Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) LUN01-24. Poster accepted to the 7th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, CA – February 22-24, 2007
• N. Hanna, M. Neubauer, R. Ansari, R. Govindan, D. Bruetman, W. Fisher, N. Chowhan, S. Nattam, C. Yiannoutsos, L. Einhorn: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): LUN01-24. Poster presentation at Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.
• F. Ademuyiwa, C. Johnson, A. White, T. Breen, J. Harvey, M. Neubauer, N.Hanna: Prognostic Factors For Survival In Patients With Unresectable Stage III Non-Small Cell Lung Cancer From a Phase III Randomized Trial From The Hoosier Oncology Group LUN01-24. Poster accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.
• M. M. Sgroi, M. Neubauer, R. Ansari, R. Govindan, D. Bruetman, W. Fisher, C. Johnson, T. Breen, C. Yiannoutsos, N. Hanna:An analysis of elderly patients (pts) treated on a phase III trial of cisplatin (P) plus etoposide (E) with concurrent radiotherapy (CRT) followed by docetaxel (D) vs observation (O) in pts with stage III non small cell lung cancer (NSCLC) LUN01-24. Poster accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.
• V. Cook, N. Hanna, T. Breen, A. White, J. Wu: Predictors of toxicity to consolidation docetaxel (D) following cisplatin (P) plus etoposide (E) plus concurrent radiation (XRT) in patients (pts) with stage III non-small cell lung cancer (NSCLC) treated on a phase III randomized trial LUN01-24. Abstract accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.
• N. Hanna, M. Neubauer, R. McGarry, C. Johnson, C. Yiannoutso, T. Breen, A. White, R. Ansari, L. Einhorn, R. Govindan: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): LUN01-24. Presentation at 12th World Conference on Lung Cancer, Seoul, Korea September 2-6, 2007.
• L. Mina, M. Neubauer, R. Ansari, R. Govindan, L. Einhorn, W. Fisher, D. Bruetman, N. Chowhan, C. Johnson, N. Hanna. Phase III Trial of Cisplatin (P) plus Etoposide (E) plus Concurrent Chest Radiation (XRT) with or without Consolidation Docetaxel (D) in Patients (pts) with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): LUN01-24/USO-023; Updated Results. Accepted as a poster presentation to the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL
• R. B. Barriger, J. C. Aseneau, M. Yu, C. Reynolds, P. Mantravadi, M. Neubauer, A. J. Fakiris, A. White, N. Hanna, R. C. McGarry. Rates and Risk of Pneumonitis in Non-Small Cell Lung Carcinoma (NSCLC) Patients (pts) Treated with Concurrent Chemoradiation LUN01-24. Submitted to the ASTRO Annual Meeting, September 21-25, 2008, Boston, MA.
• N. H. Jayaram, M. A. Neubauer, C. S. Johnson, T. Breen, C. E. Williams, N. H. Hanna. The impact of PET imaging on outcomes in patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation: A subset analysis of HOG LUN01-24/USO-023. Accepted to the general poster session at the ASCO Annual Meeting June 4-8, 2010. J Clin Oncol 28:15s, 2010 (suppl; abstr 7065)

Manuscripts/Articles:

• Hanna, Nasser; Neubauer, Marcus; McGarry, Ronald; Govindan, Ramaswamy; Johnson, Cynthia; Yiannoutsos, Constantin; Breen, Tim; White, Angela; Ansari, Rafat; Einhorn, Lawrence.Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): LUN01-24/USO-023: B5-01: Journal of Thoracic Oncology. 2(8):S346, August 2007
• Ademuyiwa F, Johnson C, White A, Breen T, Harvey J, Neubauer M, Hanna N. Prognostic factors in stage III non-small cell lung cancer LUN01-24. Clin Lung Ca 2007;8:478-82
• N. Hanna, M. Neubauer, C. Yiannoutsos, R. McGarry, J. Arseneau, R Ansari, C. Reynolds, R. Govindan, A. Melnyk, W. Fisher, D. Richards, D. Bruetman, T. Anderson, N. Chowhan, S. Nattam, P. Mantravadi, C. Johnson, T. Breen, A. White, L. Einhorn, Cisplatin plus Etoposide plus Concurrent Chest Radiation with or without Consolidation Docetaxel in Patients with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC) LUN01-24: A Randomized Phase III Study from the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008 Dec 10;26(35):5755-60. Epub 2008 Nov 10.
• Barriger, Bryan; Fakiris, Achilles; Hanna, Nasser; Yu, Menggang; Mantravadi, Prasad; McGarry, Ronald. Dose Volume Analysis of Radiation Pneumonitis in Non-Small Cell Lung Cancer Patients Treated with Concurrent Cisplatinum and Etoposide with or without Consolidation Docetaxel LUN01-24. Int. J. Radiation Oncology Biol. Phys., Vol. 78, No. 5, pp. 1381–1386, 2010 Mar 13
• Jalal SI, Riggs HD, Melnyk A, Richards D, Agarwala A, Neubauer M, Ansari R,Govindan R, Bruetman D, Fisher W, Breen T, Johnson CS, Yu M, Einhorn L, Hanna N. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology LUN01-24. Ann Oncol. 2012 Jul;23(7):1730-8. doi: 10.1093/annonc/mdr565. Epub 2011 Dec 9.